Heart failure (HF) is a leading cause of hospitalisation and healthcare costs worldwide. Acute decompensated heart failure accounts for more than 1 million hospitalisations in the US. Despite advances in the quality of acute and chronic HF disease management, gaps in knowledge about effective interventions to support the transition of care for patients with HF remain. Despite multiple trials of promising therapies, standard care consists of decongestion with IV diuretics and haemodynamic support with vasodilators and inotropes and this has remained largely unchanged during the past 45 years. Newer advances in medical innovations and structural heart disease interventions have now given promise to improved survival, outcomes and quality of life for patients with advanced HF of multiple aetiologies. In this article, we focus on structural interventions in the treatment of patients with HF.
Heart failure (HF) is a major national and international pandemic with a prevalence of more than 5.8 million in the US and over 26 million worldwide. It is the leading cause of hospitalisation and healthcare costs in the US and it accounts for more than 1 million hospitalisations annually. In the US, up to 25% of patients hospitalised with HF are readmitted within 30 days. 1 The financial burden of acute decompensated heart failure (ADHF) on the healthcare system was estimated at $30.7 billion in 2012, with a projected threefold increase by 2030, leading to a total of $160 billion total annual cost. 2 HF has multiple aetiologies and the goal of therapy is aimed not only at resolving the root cause but providing symptomatic relief in light of medication failure. The major causes of HF are distinguished between those involving heart muscle disease including those with ischaemic and non-ischaemic cardiomyopathies and those with structural abnormalities.
The adult with CHD (ACHD) or structural heart disease (SHD) represents a large proportion of the HF epidemic. With congenital heart disease (CHD) present in 0.8% to 1.0% of live births, and the advances in medical and surgical therapies for children with CHD, the growing proportion of these patients reaching adulthood now exceeds 85%
with an estimated 1.2 million patients in this group in the US. 3 SHD essentially encompasses a wide range of non-coronary cardiac disease processes, some of which include valvular disease, paravalvular leak and septal defects. Historically, the mainstay of therapy has been cardiac surgery for these types of disease, but with the advent of new minimally invasive technologies and techniques, structural intervention has changed the way this subset of patients receives treatment and has resulted in newer therapies that can be used in patients with HF.
Identification of the mechanisms responsible for HF is essential in the management of patients with SHD because these can become targets for therapies. 4, 5 Over the past decades, the rapid development of successful transcatheter procedures has led to interventional procedures becoming the primary treatment for many forms of SHD. In this article, we focus on structural interventions for the treatment of patients with HF due to both acquired and congenital defects.
Acquired Defects

Aortic Stenosis
Aortic stenosis (AS) is one of the most common valvular pathologies with sclerosis being present in 21-26% of people aged 65 years or older. The most common aetiology is senile or calcific aortic stenosis with younger people either being diagnosed at birth or with early degenerative valves (i.e. bicuspid valves). 6, 7 Patients are usually asymptomatic until late in the course of the disease when they have a high risk of acute decompensation especially when associated with congestive HF. 8 Survival analyses have demonstrated that the interval from the onset of symptoms to the time of death is about 2 years in patients with HF. 9,10 Stewart et al.
reported that among symptomatic patients with moderate-to-severe AS who had been treated medically, mortality rates after the onset of symptoms were about 25% at 1 year and 50% at 2 years. 11 More than 50% of deaths were sudden.
Transcatheter interventions are at the forefront of treatment options for severe AS. Balloon aortic valvuloplasty (BAV) has been a
long-standing option for younger patients with bicuspid valves with current practice guidelines recommending it for symptomatic young adults without severe calcification and less than moderate regurgitation with a peak-to-peak gradient of 50 mmHg, or asymptomatic young adults with ST-T changes and a peak-to-peak gradient of 60 mmHg. 11, 12 BAV is also a viable option for patients who have advanced HF who are haemodynamically unstable or as a palliative approach when the effect is time limited.
Since the onset of transcatheter aortic valve replacement (TAVR), 18
Mitral Stenosis
Mitral and Tricuspid Valve Regurgitation
Long-standing HF leads to distortion of the structural integrity of the heart causing LV dilatation and dislocation of the papillary muscles and chordae tendinae cause worsening mitral regurgitation (MR) from impaired coaptation of the mitral valve leaflets. Such secondary (functional) mitral regurgitation increases the severity of volume overload and has been strongly associated with a reduced quality of life, an increased rate of hospitalisation for HF and shortened survival. 
months of follow-up compared with medical therapy alone. 22 The study found that the annual rate of all-hospitalisation for HF was significantly lower in the device group at 35.8% compared with 67.9%
in the control group with a number needed to treat of 3.1. All-cause mortality benefit was also significantly lower in the device group at 29.1% versus 46.1% (HR: 0.62, p<0.001) with the number needed to treat to save one life within 24 months being five. 22 The MitraClip has also been approved for degenerative (primary) MR in patients who are considered high risk for surgery ( Figure 3 ).
With the advances in transcatheter therapies, new innovations for the treatment of tricuspid regurgitation has emerged MitraClip device has been used as an off-label treatment option as reported by Nickenig et al. 23 In their report, patients with HF symptoms and severe TR were randomised to medical therapy versus MitraClip for chronic, severe TR and with a successful implantation rate of 97%, they found the grade of can be altered to a suitable size by insertion of multiple stents. 25 It is crucial that only appropriate patients are selected for pulmonary valve replacement and the guidelines for surgical and transcatheter pulmonary valve replacement have continued to evolve over the past decade. [26] [27] [28] [29] [30] Pulmonary valve replacement should ideally be performed before RV function declines. In addition to clinical indications, several anatomical criteria need to be fulfilled to qualify for tPVR with the ideal anatomy being a uniform diameter from RVOT to pulmonary artery with adequate main pulmonary artery length to avoid stenting into the pulmonary artery bifurcation ( Figure 5 ). When the conduit is placed on the anterior surface of the heart, coronary branches may pass directly beneath it, and they may be compressed by the placement of the stented valve and distension of the conduit. 7 If no evidence of coronary compression is noted, pre-stenting of the RVOT is performed to create an appropriate landing zone for the transcatheter valve. Pre-stenting the landing site has significantly improved the survival of the implant, minimising stent fracture which affected 23% of the initially reported cases of the Melody valve (Medtronic). 
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Significant PVL can lead to major clinical and haemodynamic consequences and it can affect long-term survival. Symptoms may range from a decrease in functional class to severely decompensated CHF and/or haemolysis. Furthermore, persistent PVL has been shown to increase mortality. 35 Reoperation for PVL is associated with a high recurrence rate and carries significant morbidity and mortality risks. Plug-III Figure 1 ).
37,38
Congenital Defects
Pulmonary Valve Stenosis
Pulmonary valve stenosis (PVS) is a common congenital lesion found in children that may escape detection in childhood and present in adulthood with significant stenosis. It is typically caused by commissural fusion resulting in diminished valve orifice and increased RV afterload. Symptoms may vary from mild exertional dyspnoea to signs and symptoms of right HF, depending upon the severity of obstruction and the degree of myocardial compensation.
Balloon pulmonary valvuloplasty has evolved to be the procedure of choice for the treatment of pulmonary valve stenosis. Indications for intervention on isolated pulmonic stenosis include peak gradient >50 mmHg or mean gradient >30 mmHg in symptomatic patients.
In asymptomatic patients, intervention may be considered with peak gradient greater than 60 mmHg or mean gradient greater than 40 mmHg. 37 Balloon pulmonary valvuloplasty has uniformly excellent results in all age groups, with results comparable to surgical valvotomy, it has low recurrence risk and can be easily repeated if necessary. The double-balloon technique, which uses two smaller balloons from each femoral vein, has also been applied to pulmonary valve stenosis with excellent results. 39 
Atrial Septal Defects
Atrial septal defect (ASD) is the most common form of CHD to escape detection in childhood comprising between 20 and 40% of all newly or after an episode of endocarditis. 42 Device closure of VSDs has become more common and can be performed safely and effectively. 43 Only muscular VSD closure is FDA approved. Since the introduction of the Amplatzer devices to close VSDs in 1998, the outcomes of percutaneous VSD closure have significantly improved and results have been promising as these were specifically designed for closure of VSDs. 43 The wide variability in VSD location, size and morphology led to the development of different designs of the Amplatzer VSD devices (Figure 3) . Other non-Amplatzers devices are also available for use.
Additionally, perventricular 'hybrid' surgical approaches have been performed, in which a surgical incision exposes the right ventricular free wall followed by device closure in the usual fashion ( Figure 8 ).
Patent Ductus Arteriosus
The overwhelming majority of patent ductus arterioses (PDA) are structures or in the coronary artery branches. 45 Long-term effects of intravascular fistula occlusion are yet to be demonstrated.
Conclusion
As one of the leading causes of morbidity and mortality, HF has become a pandemic not only in the US but worldwide. Patients with SHD possess anatomical variations that may alter their response to medical therapy alone. Transcatheter-based structural interventions provide newer, less-invasive techniques accounting for anatomical variations that present a cornerstone of therapeutic options for these patients and the management of HF that can be expanded to the general population.
